Eligibility Module

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module

Ignite Creation Date: 2025-12-24 @ 11:52 PM
Ignite Modification Date: 2025-12-24 @ 11:52 PM
NCT ID: NCT02887651
Eligibility Criteria: Inclusion Criteria: * histologically confirmed metastasis of carcinoma (except small cell carcinoma) or malignant melanoma * 1-3 metastases in the preoperative MRI * Karnofsky Performance Status (KPS) ≥ 70 * Age \> / = 18 years * Recursive partitioning analysis (RPA) 1-2 * life expectation ≥ 6 months * no previous irradiation of the brain * MRI examinations possible * start of the radiation therapy possible within 6 weeks after surgery * informed consent Exclusion Criteria: * confirmation of residual tumor in the postoperative MRI * dementia or disease of central nervous system with a higher risk or radiogenic toxicity * contraindication for MRIs or lack of acceptance for a MRI * Glasgow Coma Scale \< 12 * Severe concomitant disease: severe cardiac, pulmonary, renal diseases with an increased risk of surgery and radiation * previous therapeutic irradiation of the brain * no histological confirmation of carcinoma metastases or malignant melanoma metastases * cerebral metastases of small cell cancer, undifferentiate neuro-endocrine carcinoma, lymphoma, leucemia, sarcoma or germ cell tumor * leptomeningeal carcinosis * distance of the cerebral metastasis to the optic system or radiation sensible brain parts \< 10 mm * metastases of the brain stem, Di- or Mesencephalons, Pons oder Medulla oblongata * bone marrow dysfunction * contrast agent allergy * pregnancy
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT02887651
Study Brief:
Protocol Section: NCT02887651